A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia

Leukemia Research

Volumn 35, Issue 8, 2011, Pages 1074-1079

  He, Qun ^a   Dong, Jun ^a   Zhen, Huanying ^a   Ying, Yalin ^a   Zhang, Jun ^a   Li, Qiong ^a   Li, Birong ^a   Zhou, Yang ^a  

^a Central South University   (China)

Author keywords

2 Aminosteroid; Bcr abl; CML; H89465; K562; Meg 01; T315I

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; H 89465; IMATINIB; MESSENGER RNA; STEROID; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCR ABL GENE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; FUSION GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPRECIPITATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED NOD; MICE, SCID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEROIDS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 79960211016     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.012     Document Type: Article

References (21)

1. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
2. De Klein A., Geurts van Kessel A., Grosveld G. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myeloid leukemia. Nature 1982, 300:290-293.
3. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
4. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
5. Schindler T., Bornmann W., Pellicena P. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000, 289:1938-1942.
6. Gorre M.E., Mohammed M., Ellwood K. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
7. von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002, 359:487-491.
8. Quintás-Cardama A., Kantarjian H.M., Cortes J.E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16:122-131.
9. Tanaka R., Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther 2008, 8:1387-1398.
10. Thomas M., Greil J., Heidenreich O. Targeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials. Acta Pharmacol Sinica 2006, 27:273-281.
11. Klein E., Ben-Bassat H., Neumann H. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer 1976, 18:421-431.
12. Ogura M., Morishima Y., Ohno R. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985, 66:1384-1392.
13. Qi J., Peng H., Gu Z.L., Liang Z.Q., Yang C.Z. Establishment of an imatinib resistant cell line K562/G01 and its characterization. Chin J Hematol 2004, 25:337-341.
14. Baran Y., Ural A.U., Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007, 12:497-503.
15. He Q., Jiang D.Z. A novel aminosteroid is active for proliferation inhibition and differentiation induction of human acute myeloid leukemia HL-60 cells. Leuk Res 1999, 23:369-372.
16. He Q., Na X.D. The effects and mechanisms of a novel 2-aminosteroid on murine WEHI-3B leukemia cell in vitro and in vivo. Leuk Res 2001, 25:455-461.
17. He Q., Li Q., Yuan L.B., He J. A new 2-aminosteroid induces cellular differentiation and upregulates the expression of MafB and Egr-1 genes respectively in HL-60 and K562 leukemia cells. Chin Med J 2005, 118:91-99.
18. He Q, Dong J, Zhen HY, Zhang J. Chinese Patent. CN101456890 (2009).
19. Mauro M.J. Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer Control 2009, 16:108-121.
20. Breccia M., Alimena G. Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets 2009, 9:21-28.
21. Jabbour E., Cortes J., Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009, 4:3-10.